Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Beta-cell mass is reduced by up to 95% in stage 4 T1D

  80% confidence

• This priority review emphasizes the urgent need for innovative therapies like Tzield which has the potential to prevent the natural progression of T1D by delaying the loss of endogenous insulin production

  80% confidence

• Tzield slows disease progression by protecting the insulin-secreting beta cells of the pancreas

  80% confidence

• The autoimmune attack that drives T1D in many cases begins early in life

  80% confidence

• Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D in children aged one and older diagnosed with stage 2 T1D if approved

  80% confidence

• If approved, Tzield could represent an important advance for delaying the onset of stage 3 type 1 diabetes in early childhood, which would benefit patients and caregivers alike

  80% confidence